We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

218 hedge funds and large institutions have $3.68B invested in Neurocrine Biosciences in 2017 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 72 increasing their positions, 80 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $3.27B → $3.68B (+$417M)

3% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 37

0.51% more ownership

Funds ownership: 97.13% → 97.64% (+0.51%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

3% less funds holding

Funds holding: 225 → 218 (-7)

10% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 80

39% less call options, than puts

Call options by funds: $12.3M | Put options by funds: $20.3M

Holders
218
Holders Change
-7
Holders Change %
-3.11%
% of All Funds
5.43%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
38
Increased
72
Reduced
80
Closed
37
Calls
$12.3M
Puts
$20.3M
Net Calls
-$8.01M
Net Calls Change
-$6.53M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$214M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$87.4M
3
JHIU
Janus Henderson Investors US
Colorado
+$85.8M
4
Goldman Sachs
Goldman Sachs
New York
+$42.7M
5
Citadel Advisors
Citadel Advisors
Florida
+$30.7M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$80M
2
O
OrbiMed
New York
-$72.3M
3
Millennium Management
Millennium Management
New York
-$51.7M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$39.4M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$26.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
FPFS
201
First Personal Financial Services
North Carolina
$23K +$5.44K +127 +31%
CAM
202
Close Asset Management
United Kingdom
$16K – – –
SEC
203
Seven Eight Capital
New York
$13K +$12.9K +300 New
US Bancorp
204
US Bancorp
Minnesota
$12K -$7.41K -173 -37%
CLOS
205
Compagnie Lombard Odier SCmA
Switzerland
$11K – – –
SIM
206
Sonora Investment Management
Arizona
$8.66K +$8.57K +200 New
AIM
207
Advantage Investment Management
Iowa
$7K – – –
PA
208
Parallel Advisors
California
$5K +$386 +9 +11%
TRCT
209
Tower Research Capital (TRC)
New York
$5K +$2.36K +55 +106%
IA
210
IFP Advisors
Florida
$4K – – –
ASN
211
Advisory Services Network
Georgia
$4K +$4.28K +100 New
PCP
212
Proficio Capital Partners
Massachusetts
$3K +$2.4K +56 New
FMA
213
FNY Managed Accounts
New York
$3K +$3.51K +82 New
EFSCE
214
Enterprise Financial Services Corp (EFSC)
Missouri
$1K -$1.8K -42 -65%
WA
215
Winfield Associates
Ohio
$1K +$643 +15 New
MPWT
216
MassMutual Private Wealth & Trust
Connecticut
$433 -$2.36K -55 -85%
Walleye Trading
217
Walleye Trading
New York
$3 +$3.21K +75 New
Millennium Management
218
Millennium Management
New York
– -$51.7M -1,335,798 Closed
ACA
219
Avoro Capital Advisors
New York
– -$20.9M -541,000 Closed
Allianz Asset Management
220
Allianz Asset Management
Germany
– -$8.7M -224,869 Closed
JP
221
Jana Partners
New York
– -$7.02M -181,296 Closed
AAMU
222
Amundi Asset Management US
Massachusetts
– -$5.93M -153,347 Closed
NC
223
Nexthera Capital
New York
– -$4.64M -120,000 Closed
Two Sigma Investments
224
Two Sigma Investments
New York
– -$3.25M -83,923 Closed
ARTA
225
A.R.T. Advisors
New York
– -$2.07M -53,600 Closed
7 8
9
10 11

NBIX Hedge Fund Activity: Q1 2017 in Review

218 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2017, worth a combined $3.68B — up 13% from $3.27B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new NBIX positions and 37 closed out — a net gain of 1 holder — while 72 added to existing stakes and 80 trimmed.

The largest buyer was BlackRock, adding an estimated $214M. The largest seller was T. Rowe Price Associates, cutting an estimated $80M.

  • 218 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2017, down from 225 in Q4 2016.
  • Funds reported $3.68B of Neurocrine Biosciences stock for Q1 2017, up 13% quarter-over-quarter.
  • 38 funds opened new Neurocrine Biosciences positions in Q1 2017 and 37 closed out, a net change of +1 holder.
  • The largest Neurocrine Biosciences buyer in Q1 2017 was BlackRock, an estimated $214M added.
  • The largest Neurocrine Biosciences seller in Q1 2017 was T. Rowe Price Associates, an estimated $80M sold.

Based on aggregated 13F filings for Q1 2017.